CompletedPhase 1/2

Tissue Inhibitor of Metalloproteinases 2 Level in Patients Undergoing Cardiac Surgery

China100 participantsStarted 2023-07-22

Plain-language summary

Acute kidney injury (AKI) is one of the most frequent major complications in patients undergoing cardiac surgery. CSA-AKI is independently related to increased perioperative mortality, increased hospital and ICU length of stay as well as heath care expenditure. Identification of relevant biomarkers may lead to early diagnosis and improve patient outcomes and health care costs. The pathophysiology of CSA-AKI is complex and ischemia-reperfusion injury is one of the important factors. Recently, it has been shown that Tissue Inhibitor of Metalloproteinases 2 (TIMP2) is associated with ischemia-reperfusion injury. In this study, relationship between TIMP2 with the risk of CSA-AKI was analyzed and the predictive value of elevated level of TIMP2 for early prediction of CSA-AKI was further evaluated.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients (≥18 years old) underwent on-pump cardiac surgery * admitted to ICU immediately after surgery Exclusion Criteria: * Patients younger than 18 years * with prior AKI * end-stage kidney disease * need for chronic hemodialysis * pregnant patients * unable to give written consent for participation

What they're measuring

the development of CSA-AKI

Timeframe: 1 Week

Trial details

NCT IDNCT06871826

SponsorWuhan University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-01-25

View on ClinicalTrials.gov More Acute Kidney Injury trials